middle.news
Alterity Advances ATH434 Phase 3 Program with FDA Endorsement on Manufacturing
9:21am on Monday 27th of April, 2026 AEST
•
Biotechnology
Read Story
Alterity Advances ATH434 Phase 3 Program with FDA Endorsement on Manufacturing
9:21am on Monday 27th of April, 2026 AEST
Key Points
FDA endorses chemistry, manufacturing, and control plans for ATH434 Phase 3
Manufacturing scale-up progressing alongside regulatory preparations
Phase 3 pivotal trial for rare neurodegenerative disease MSA remains on track
ATH434 previously demonstrated meaningful efficacy in Phase 2 trials
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE